US patients sue Novo Nordisk, Eli Lilly over GLP-1 vision loss claims

US patients have filed lawsuits against Novo Nordisk and Eli Lilly, alleging that their GLP-1 drugs (Ozempic, Mounjaro) caused vision loss. The claims are emerging amid growing global use of these medicines, including unregulated online sales in Nigeria. The legal outcome and any regulatory action remain uncertain, but the case could affect drugmaker liability and prescribing practices.